Researchers Uncover Safe Target for Acute Myeloid Leukemia Treatment

Researchers at the Josep Carreras Leukaemia Research Institute have identified a promising new target for treating acute myeloid leukemia (AML). The study, led by Dr. Marcus Buschbeck and Dr. René Winkler, found that targeting a specific group of histones, known as macroH2A, is safe and could open new therapeutic avenues for blood cancers.

The findings reveal that the removal of any of the three proteins from the macroH2A family is well tolerated in mice, showing no significant negative effects on their health. Blood cancers like AML often respond temporarily to existing treatments, but the majority of patients experience relapse, necessitating the search for new therapies.

Exploring New Therapeutic Avenues

The Josep Carreras Leukaemia Research Institute is actively seeking novel druggable targets within chromatin, the biochemical component where genetic information is stored and regulated. Histones play a vital role in maintaining chromatin structure and genome stability. Mutations in histones are known contributors to blood cancers, making certain histone genes potential targets for therapy.

For years, targeting histones was deemed impractical due to their essential role in cell survival, leading to concerns that drugs could have severe side effects. Ari Melnick, Director of the Josep Carreras Institute, emphasized the importance of this research, stating that the inability to develop treatments targeting histones has limited options for addressing a significant mechanism driving blood cancers.

Dr. Buschbeck’s team identified macroH2A histones as viable candidates for therapy. Previous research established a connection between macroH2A and AML, prompting further investigation into their potential as drug targets.

Promising Experimental Results

In a recent publication in Science Advances, the research team conducted a series of experiments to assess the impact of removing each of the three macroH2A variants in healthy mice. These studies were supported by collaboration with physiology experts at the Helmholtz Center Munich and the German Mouse Clinic, which monitors over 500 parameters in mice to detect even minor treatment effects.

Surprisingly, the results indicated that the mice experienced no significant adverse effects following the removal of the macroH2A histone variants. The only notable observation was a mild kidney condition linked to the removal of the macroH2A1.1 variant, which stemmed from a shift in the mice’s metabolism from fat to sugar. The research team successfully managed this condition through dietary adjustments, demonstrating that the changes posed no threat to the animals.

Overall, the team concluded that targeting macroH2A histone variants is a safe approach for potential treatments in patients with AML. This research has sparked a new line of investigation at the Josep Carreras Leukaemia Research Institute and its international collaborators, aiming to test macroH2A variants as possible drug targets for leukemia and other blood cancers.

These findings mark a significant step forward in addressing the urgent need for effective treatments in blood cancers, with the potential to improve patient outcomes significantly. Further research will be vital for translating these discoveries into clinical applications.